A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relapse free survival and overall survival of
Imatinib (Gleevec) or high dose Interferon (Intron) in treating melanoma which has primary
tumor and regional lymphonode (if have) removed in patients whose disease carries a c-kit
mutation. It is assumed that Gleevec may be more effective on relapse free survival as the
adjuvant treatment compared with Interferon.